Theravance Biopharma (NASDAQ:TBPH) Trading 5.7% Higher Following Analyst Upgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares shot up 5.7% on Friday after BTIG Research raised their price target on the stock from $24.00 to $25.00. BTIG Research currently has a buy rating on the stock. Theravance Biopharma traded as high as $11.22 and last traded at $11.35. 77,972 shares changed hands during trading, a decline of 71% from the average session volume of 268,919 shares. The stock had previously closed at $10.73.

A number of other equities analysts also recently issued reports on TBPH. Jones Trading upgraded Theravance Biopharma to a “strong-buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Wall Street Zen raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 21st. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.60.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now owns 370,038 shares in the company, valued at $3,330,342. This trade represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Large investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in shares of Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company’s stock worth $556,000 after acquiring an additional 2,293 shares during the period. Geode Capital Management LLC lifted its stake in Theravance Biopharma by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company’s stock worth $8,121,000 after purchasing an additional 4,823 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Theravance Biopharma by 16.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company’s stock worth $610,000 after purchasing an additional 9,315 shares during the last quarter. ProShare Advisors LLC bought a new stake in Theravance Biopharma during the fourth quarter worth about $119,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Theravance Biopharma by 27.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company’s stock worth $1,412,000 after purchasing an additional 32,534 shares during the last quarter. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Price Performance

The stock has a market cap of $561 million, a P/E ratio of -9.51 and a beta of -0.09. The company has a 50 day simple moving average of $10.00 and a 200-day simple moving average of $9.51.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. The business had revenue of $15.39 million during the quarter, compared to analysts’ expectations of $28.08 million. As a group, research analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.